A Phase 1 Study of AMG 330 in Subjects With Myeloid Malignancies

Clinical trial NCT02520427 · TERMINATED

Trial details

NCT number: NCT02520427
Sponsor: Amgen
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

Relapsed/Refractory AML Minimal Residual Disease Positive AML Myelodysplastic Syndrome

Start date: 2015-08-31
Primary completion: 2022-01-09
Enrollment: 95

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.